GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency

Justin Arredondo-Guerrero(Stanford University), Dorota D. Klysz(Stanford University), Yiyun Chen(Stanford University), Meena Malipatlolla(Stanford University), Jameel Lone(Stanford University), Carley Fowler(Stanford University), Lucille Stuani(Stanford University), Audre May(Stanford University), Malek Bashti(Stanford University), Peng Xu(Stanford University), Jing Huang(Stanford University), Basil Michael(Stanford University), Kévin Contrepois(Stanford University), Shaurya Dhingra(Stanford University), Chris Fisher(Stanford University), Katrin J. Svensson(Cardiovascular Institute of the South), Kara L. Davis(Stanford University), Maya Kasowski(Stanford Medicine), Steven A. Feldman(Stanford University), Elena Sotillo(Stanford Medicine), Crystal L. Mackall(Parker Institute for Cancer Immunotherapy)
Nature Communications
October 6, 2024
Cited by 83Open Access
Full Text

Abstract

Abstract The intensive nutrient requirements needed to sustain T cell activation and proliferation, combined with competition for nutrients within the tumor microenvironment, raise the prospect that glucose availability may limit CAR-T cell function. Here, we seek to test the hypothesis that stable overexpression (OE) of the glucose transporter GLUT1 in primary human CAR-T cells would improve their function and antitumor potency. We observe that GLUT1OE in CAR-T cells increases glucose consumption, glycolysis, glycolytic reserve, and oxidative phosphorylation, and these effects are associated with decreased T cell exhaustion and increased Th 17 differentiation. GLUT1OE also induces broad metabolic reprogramming associated with increased glutathione-mediated resistance to reactive oxygen species, and increased inosine accumulation. When challenged with tumors, GLUT1OE CAR-T cells secrete more proinflammatory cytokines and show enhanced cytotoxicity in vitro, and demonstrate superior tumor control and persistence in mouse models. Our collective findings support a paradigm wherein glucose availability is rate limiting for effector CAR-T cell function and demonstrate that enhancing glucose availability via GLUT1OE could augment antitumor immune function.


Related Papers

No related papers found

Powered by citation graph analysis